Histoplasmosis and SARS-CoV-2 infection in a critically ill patients
Keywords:
COVID-19, SARS-CoV-2, histoplasmosis, immunocompetent.Abstract
Introduction: Histoplasmosis is caused by the dimorphic fungus Histoplasma capsulatum, whose clinical manifestations range from asymptomatic to disseminated and highly fatal disease.Objective: To present the case of a patient diagnosed with disseminated histoplasmosis and SARS-CoV-2 infection.
Clinical case: The case of a 79-year-old man is presented with a history of systemic arterial hypertension and type 2 diabetes mellitus. He was admitted for a week with nonproductive cough, dyspnea, and fatigue on moderate exertion, and reported having a positive antigen test for SARS- CoV-2. During hospitalization, he presented clinical deterioration, needing mechanical ventilation due to respiratory infection associated with COVID-19. Despite this, he presented lymphadenopathy, hepatosplenomegaly, and umbilicated skin-colored papules suggestive of disseminated fungal infection. Suspecting co-infection, infection by Histoplasma capsulatum was confirmed by means of mini-bronchoalveolar lavage and antifungal treatment was initiated; however, the patient presented persistent clinical deterioration and died.
Conclusion: Cases of co-infections with COVID-19 in patients without chronic diseases or immunosuppressive states are rare, their diagnosis being a challenge for medical personnel and requiring consideration of pulmonary fungal infections such as cryptococcosis or histoplasmosis in associated respiratory failure. to SARS-CoV-2 infection.
Downloads
Download data is not yet available.
References
1. Johns Hopkins University of Medicine Coronavirus Resource Center. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. Tracking Home; 2020. [acceso: 22/06/2022]. Disponible en: https://coronavirus.jhu.edu/map.html
2. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021; 27(1):9-11. DOI: 10.1016/j.cmi.2020.09.025
3. Araúz AB, Papineni P. Histoplasmosis. Infect Dis Clin North Am. 2021; 35(2):471-91. DOI: 10.1016/j.idc.2021.03.011
4. Myint T, Leedy N, Villacorta Cari E, Wheat LJ. HIV-Associated Histoplasmosis: Current Perspectives. HIV AIDS (Auckl). 2020; 12:113-125. DOI: 10.2147/HIV.S185631
5. Basso RP, Poester VR, Benelli JL, Stevens DA, Zogbi HE, Vasconcellos ICDS, et al. COVID-19-Associated Histoplasmosis in an AIDS Patient. Mycopathologia. 2021; 186(1):109-12. DOI: 10.1007/s11046-020-00505-1
6. Bertolini M, Mutti MF, Barletta JA, Falak A, Cuatz D, Sisto A, et al. COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report. Int J STD AIDS. 2020; 31(12):1222-4. DOI: 10.1177/0956462420957518
7. Cafardi J, Haas D, Lamarre T, Feinberg J. Opportunistic Fungal Infection Associated With COVID-19. Open Forum Infect Dis. 2021; 8(7):ofab016. DOI: 10.1093/ofid/ofab016
8. Tuta E, Vega M, Perdomo L, Pimentel J. Colchicina, perspectivas de un viejo amigo para la reumatología en la COVID-19: una revisión exploratoria. Rev Col Reum. 2022; 29:35-S47. DOI: 10.1016/j.rcreu.2021.02.002
9. Myint T, Leedy N, Villacorta Cari E, Wheat LJ. HIV-Associated Histoplasmosis: Current Perspectives. HIV AIDS (Auckl). 2020; 12:113-25. DOI: 10.2147/HIV.S185631
10. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2020; 16(5):442-9. DOI: 10.2174/1573399815666191024085838
11. Benedict K, Beer KD, Jackson BR. Histoplasmosis-related Healthcare Use, Diagnosis, and Treatment in a Commercially Insured Population, United States. Clin Infect Dis. 2020; 70(6):1003-10. DOI: 10.1093/cid/ciz324
12. Morote S, Nacher M, Blaizot R, Ntab B, Blanchet D, Drak Alsibai K, et al. Comparison of Disseminated Histoplasmosis with and without Cutaneo-Mucous Lesions in Persons Living with HIV in French Guiana. J Fungi (Basel). 2020; 6(3):133. DOI: 10.3390/jof6030133
2. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021; 27(1):9-11. DOI: 10.1016/j.cmi.2020.09.025
3. Araúz AB, Papineni P. Histoplasmosis. Infect Dis Clin North Am. 2021; 35(2):471-91. DOI: 10.1016/j.idc.2021.03.011
4. Myint T, Leedy N, Villacorta Cari E, Wheat LJ. HIV-Associated Histoplasmosis: Current Perspectives. HIV AIDS (Auckl). 2020; 12:113-125. DOI: 10.2147/HIV.S185631
5. Basso RP, Poester VR, Benelli JL, Stevens DA, Zogbi HE, Vasconcellos ICDS, et al. COVID-19-Associated Histoplasmosis in an AIDS Patient. Mycopathologia. 2021; 186(1):109-12. DOI: 10.1007/s11046-020-00505-1
6. Bertolini M, Mutti MF, Barletta JA, Falak A, Cuatz D, Sisto A, et al. COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report. Int J STD AIDS. 2020; 31(12):1222-4. DOI: 10.1177/0956462420957518
7. Cafardi J, Haas D, Lamarre T, Feinberg J. Opportunistic Fungal Infection Associated With COVID-19. Open Forum Infect Dis. 2021; 8(7):ofab016. DOI: 10.1093/ofid/ofab016
8. Tuta E, Vega M, Perdomo L, Pimentel J. Colchicina, perspectivas de un viejo amigo para la reumatología en la COVID-19: una revisión exploratoria. Rev Col Reum. 2022; 29:35-S47. DOI: 10.1016/j.rcreu.2021.02.002
9. Myint T, Leedy N, Villacorta Cari E, Wheat LJ. HIV-Associated Histoplasmosis: Current Perspectives. HIV AIDS (Auckl). 2020; 12:113-25. DOI: 10.2147/HIV.S185631
10. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr Diabetes Rev. 2020; 16(5):442-9. DOI: 10.2174/1573399815666191024085838
11. Benedict K, Beer KD, Jackson BR. Histoplasmosis-related Healthcare Use, Diagnosis, and Treatment in a Commercially Insured Population, United States. Clin Infect Dis. 2020; 70(6):1003-10. DOI: 10.1093/cid/ciz324
12. Morote S, Nacher M, Blaizot R, Ntab B, Blanchet D, Drak Alsibai K, et al. Comparison of Disseminated Histoplasmosis with and without Cutaneo-Mucous Lesions in Persons Living with HIV in French Guiana. J Fungi (Basel). 2020; 6(3):133. DOI: 10.3390/jof6030133
Published
2023-01-17
How to Cite
1.
Serna I, Cabezas L, Benitez Caraballo S, Tuta-Quintero E, Mantilla Y, Ochoa Guette D, et al. Histoplasmosis and SARS-CoV-2 infection in a critically ill patients. Rev Cubana Med Milit [Internet]. 2023 Jan. 17 [cited 2025 Apr. 2];52(1):e02302225. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/2225
Issue
Section
Case Presentation
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
